Drug Discovery
By
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era of Affordable Innovation and Domestic Manufacturing?
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma – The Dawn of Robotics-Driven R&D at Scale?
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Endpoints Signal Report Finds Nearly Half of Biopharma Professionals Are Heavy AI Users, With Expectations of Major R&D Transformation Ahead
Based on Endpoints Signal Pulse Report | December 2025 A new Signal Pulse Report from Endpoints News reveals…
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
